Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The start of today’s trading with ARYC looks a lot like two heavy-weight fighters feeling each other out before landing a haymaker...lol
Yep, I agree. This is going to be interesting.
I don’t know how iconic will come up with the money for this, especially if they do have to buy back all the shares they sold. Arrayit is definitely in a great position.
Yep, I definitely see that. Let's see what happens Monday.
Everything falling in line.
Perfect
Yeah, I saw that on the other board just a few minutes ago. I had to look a little hard for it. Looks good!
Last paragraph. 2 years worth of damages to Arrayit
I didn't see the decision...what was the ruling?
The extensive research provided down below leads me to believe that ArrayIT Corp (ticker symbol: ARYC) is undervalued and loading at these levels could be worth wild.
SEC form 15 was submitted and approved.
"Option C is especially attractive to a Company that is in excess of two years delinquent in its reporting requirements and cannot reasonably obtain the records necessary to complete its audits for those years beyond the two-year period."
http://www.legalandcompliance.com/securities-resources/bringing-delinquent-exchange-act-reporting-companies-current/
ArrayIT is a CLIA approved laboratory.
https://www.cms.gov/apps/clia/clia_start.asp?CLIANum=05D2147467&LabName=&GeoCity=&state=AK&GeoZip=&appType=%25&isSubmitted=clia2
Dr. Mark Schena discusses an all encompassing allergy test on The Four
https://www.ktvu.com/video/628515
https://m.facebook.com/Pediatricallergysolutions/videos/?ref=page_internal&mt_nav=0
Investors Briefing:
https://vimeo.com/389346699
The term investors briefing would make it seem that the participation of seminars and investor events are going to start taking place as global lab expansion and possible joint ventures are explored.
Studies performed in Saudi Arabia and from pilot programs are now being provided. The studies shown are remarkable (please review them as they are referenced & dated on the link below).
https://m.facebook.com/Pediatricallergysolutions/
"Optimum Allergy Solutions’ Test and Treat Program for Allergies and Asthma” at the request of the DIAD health authority from Dubai, UAE, and the Ministry of Health, Saudi Arabia.”
https://pressrelease.healthcare/leading-hematologist-oncologist-and-internist-michael-t-parra-md-is-to-be-recognized-as-a-2018-top-doctor-in-denver-colorado.html
Pilot Program by Kroger’s The Little Clinic confirmed by an executive from Kroger.
https://www.bing.com/videos/search?q=allerdent&view=detail&mid=508D4C15923F0BE5040E508D4C15923F0BE5040E&FORM=VRRTAP
ArrayIT announces the completion of a pilot program for one of the nation’s largest retail chains.
https://www.globenewswire.com/news-release/2018/07/02/1532240/0/en/Arrayit-Corporation-Completes-Allergy-Testing-Pilot-Program-for-One-of-the-Nation-s-Largest-Retail-Chains.html
By viewing the below links it would be understood that PAS/OAS is a marketing company that spawned out from VantageRx due to the growing demand from the allergy fingerstick test coupled with the Allerdent immunotherapy treatment option.
https://vantagerx.com/index.html
VantageRx has a nationwide network of over 1,800 independent representatives to educate healthcare practices on unique ancillary products and services. The flagship program is Optimum Allergy Solutions - a revolutionary allergy test & treatment program where providers test & treat for allergies in their office (a fingerstick blood test for 180 allergens and treat with prescribed toothpaste.)
https://www.linkedin.com/in/rick-orchard-20a27324
https://www.ptcommunity.com/wire/arrayit-corporation-announces-nationwide-allergy-testing-sales-and-distribution-network
https://www.globenewswire.com/news-release/2017/12/19/1266153/0/en/New-Test-and-Treatment-Allergy-Program-Enables-All-Physicians-To-Provide-Convenient-And-Effective-Allergy-Care.html
https://www.ptcommunity.com/wire/arrayit-corporation-announces-allergy-testing-partnerships-major-allergy-therapeutics-providers
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149154347
They nailed a huge VA contract that became effective this month (February 2020). This is mentioned as a direct contract, which avoids the hassle of dealing with insurance companies (refer to the investors briefing video up top). The video link further depicts a potential revenue chart, which would show the company possibly being able to bill around $1 million per day by summer 2020.
https://storage.googleapis.com/wzukusers/user-27922100/documents/5be9c697a0feacHGfCzT/01)%20PAS%20-%20Sales%20-%20Sample%20Report%20-%20110118-2.pdf
https://optimumallergysolutions.com/va
https://optimumallergysolutions.com/telemed-va/
Animal Allergy Comprehensive Test:
https://optimumallergysolutions.com/animals
The FDA has purchased ArrayIT products and the company also has a major product line pending the approval of the FDA.
https://www.fpds.gov/ezsearch/fpdsportal?q=arrayit&s=FPDSNG.COM&templateN=&&templateName=1.5.1&indexName=awardfull
https://www.accessdata.fda.gov/scripts/sda/sdDetailNavigation.cfm?sd=srolist&id=9CC1CCBA6A6080E6E053564DA8C05A23&rownum=1
ArrayIT pipeline tests can be viewed on their newly updated website.
http://arrayit.com/
USDA:
https://www.ars.usda.gov/research/project/?accnNo=430420
Cutting Edge Technology
Twin Arbor Analytical utilizes cutting edge technologies such as Arrayit’s (ARYC) proprietary microarray platform. This system was developed as a research cooperative agreement with the United States Department of Agriculture – Agricultural Research Services (USDA-ARS) as a low-cost high throughput system for the analysis of microbial contaminants such as E. coli, salmonella, listeria, Noro virus and Hepatitis A.
https://www.twinarborlabs.com/
Medicare & Medicaid services:
https://www.patientdatasolutions.com/medicare.jsp
https://npiregistry.cms.hhs.gov/registry/provider-view/1104316157
After the Form 15 is lifted IMO
I agree! Maybe we will see some PR’s soon!
With that ruling by the judge posted yesterday on the ARYC board, I would expect a strong move up tomorrow. Everything is lining up perfect
Fantastic news for ARYC.
It feels like Iconic is going to be on the hook here, and guaranteed they are bleeding money into this for lawyer and court costs.
I believe you are right in your assessment. That coupled with the potential "short squeeze" that may occur because of the court ruling should improve pps in the near future.
Very interesting....I’ll take a starter on Monday...really like the potential...thanks Sloan
What a big victory for $ARYC!!
2-7-2020. ARYC Judge’s decision!
$$ land coming! Release those 10K’s and Arrayit will run like no other pennystock ever has!
PSA may be right in saying that Arrayit is an undiscovered gem at this level. Currently ARYC is trading around 0.019...which is 70.81% off its 200-Day moving average of 0.0303. And one year ago it was trading at 0.07. Arguably the reason for the price decline is the lack of communications from the company subsequent to filing its SEC Form 15. Once ARYC begins communicating again with Press Releases and SEC reports, the stock could rebound quickly. Having visited the company last year I am content to wait for this to happen. During 2019 the company made significant changes in its business model and is seeing very positive results.
All: Review Stock Detectives links
ARYC is an undiscovered gem at this level!
$ARYC tweeted several B2B opportunities in the European Union.
I don’t believe many understand the significance in the totality of events that have occurred and that are about to occur.
Pediatric Allergy Solutions (PAS) has an exclusive agreement with Allerdent an immunotherapy company who is working on FDA approval on a peanut allergy treatment. 2021 will be a great year if FDA approval is granted and we should see an exponential growth in revenues.
The VA direct contract effective February 2020.
CVS & Walmart contracts are in the works.
Kroger’s The Little Clinic pilot program was completed.
Lab expansion in the works... Globally!
By following the potential revenue chart provided in the most recent video one can form an opinion that billing could potentially increase to $1million per day by March-April of this year.
The animal companion allergy testing option has recently been added on marketing partner(s) website(s).
* Tech sales
* USDA
* FDA
* There is a major product line pending FDA approval.
2021-2022 billion dollar company?
It would be interesting to find out what they have accomplished in Europe since the patent was awarded last year.
Allovate Therapeutics Announces Grant of European Patent Covering Oral Mucosal Immunotherapy Platform
https://www.benzinga.com/pressreleases/19/03/g13327065/allovate-therapeutics-announces-grant-of-european-patent-covering-oral
Todos (TOMDF), venture partner of AMBS releases PR below. Interestingly they are looking at uplisting to NASDAQ the first half of 2020.
Todos Medical Releases Letter to Shareholders
9:15 AM ET 2/7/20 | GlobeNewswire
REHOVOT, Israel, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today released a letter to shareholders:
Dear Shareholders,
Thank you for continuing to support the Company as we embark on this effort to transform into a US-focused blood diagnostics company preparing to embark on a clinical utility study with a view towards obtaining our own CPT code to allow for value-based, consistent reimbursement of an actionable blood test for breast cancer. I was asked by the Company's Board of Directors to step in as CEO in early January, in large part, due to the prospective acquisition of Provista Diagnostics, which is a US-based blood testing company that has received over $50 million in investment to develop the Videssa(R) blood test for breast cancer.
Please find here a link to the Company's updated corporate presentation: http://investor.todosmedical.com/static-files/815190c5-2c1f-4e21-9309-dd5aab5802d1 . The Company is staying strategically focused in the area of breast cancer, while continuing to develop our Alzheimer's diagnostic platform.
Breast Cancer
Over the past several weeks, as we have begun to put the infrastructure in place to re-domicile Todos from Israel to the US, I have been repeatedly asked why a company that owns TM-B2, a breast cancer blood test for the dense breast population (BI-RADS III/IV), would buy a competitor that owns Videssa, a competing breast cancer blood test for the dense breast population. Is it because you don't believe in TM-B2? To be clear, we unequivocally believe in TM-B2. Our rationale for the business combination is as follows:
1. Videssa has been prospectively tested in over 1,100 subjects, vs. over
400 subjects for TM-B2;
2. As Videssa has significantly more prospective clinical validation data,
it has achieved a level of clinical validation that allows it to progress
to a clinical utility (reimbursement) study;
3. Videssa has shown very strong negative predictive value (NPV) for breast
cancer, but poor positive predictive value (PPV), whereas TM-B2 has shown
strong NPV and PPV;
4. We have the opportunity to dramatically accelerate the acquisition of
data for TM-B2 by 'piggybacking' its development onto the clinical
utility study for Provista, i.e. we will collect data for both Videssa
and TM-B2 during Videssa's clinical utility study:-- This will have the
benefit of true 'head to head' data comparing Videssa and TM-B2;-- Due to
the extremely low cost of running the TM-B2 assay, the incremental cost
to the Videssa clinical utility study is expected to be relatively
insignificant;-- The study is being designed to define the value of NPV
in breast cancer for Videssa, and would have the upside potential of
demonstrating the value of TM-B2-- The data obtained could potentially
support the value of PPV in breast cancer for TM-B2, but at a minimum
will provide us with significant analytical and clinical validation data
for TM-B2;
5. The market opportunity for a blood test that can triage subjects who have
dense breast is so large that regardless of which technology is
ultimately the best, Todos shareholders stand to benefit substantially
from any positive clinical results;
6. The underlying Todos Total Biochemical Infrared Analysis (TBIA) platform
can be leveraged by virtue of the data collected in the Videssa clinical
utility study to create additional exploratory and proof of concept data
for other cancers, and potentially other diseases.
Alzheimer's Disease
Todos is also preparing to receive confirmatory data from the second half of an ongoing clinical trial of the Alzheimer's blood diagnostic LymPro Test through our joint venture, Breakthrough Diagnostics. The importance of this milestone cannot be overstated by virtue of the initial data that we received that demonstrated a very strong correlation with amyloid PET imaging ( p = 0.000002, r = .849). We strongly believe that Alzheimer's disease is effectively cancer of post-mitotic brain cells (cells that are physiologically no longer able to complete the cell division process), and this upcoming data will provide further evidence of the immune system's importance in Alzheimer's disease. Recent data published in the Journal of Experimental Medicine hypothesize that signaling molecules linked to the immune system immune cells in the brain have the potential to alleviate age-related cognitive decline. We believe this provides further evidence that LymPro is on the right track in terms of understanding the role of the immune system in Alzheimer's disease. A breakthrough in this area could have significant implications for health systems worldwide, especially identifying a peripheral biomarker that could identify individuals at the earliest stages of disease.
Summary
In light of the significant market opportunity the Company has in the areas of cancer and Alzheimer's, we believe there is tremendous value to be unlocked from the underlying technologies to which Todos has rights. Going forward, the Company will be focused on bridging the gap to allow the Company to achieve interim milestones on its way to a proposed listing on Nasdaq in the first half of 2020.
I would like to sincerely thank you for your continued support of the Company, and I look forward to providing further updates in the near future.
Warmest Regards,
Gerald Commissiong
CEO
About Todos Medical Ltd.
Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer's influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company's two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Breakthrough Diagnostics is developing the LymPro Test(R) , a blood test for diagnosing Alzheimer's disease. Todos has also entered into an exclusive option to acquire breast cancer blood testing company Provista Diagnostics, Inc. that is commercializing the Videssa(R) breast cancer blood test.
For more information, the content of which is not part of this press release, please visit http://www.todosmedical.com
Silicon Valley biotech stock ARYC [Arrayit Corporation] trading under .02, has developed a next generation allergy fingerstick test... An amazing breakthrough in the medical field.
Cerner Corp. employees and some of its clients will be able to pull their health records into the Apple Health app, thanks to a recent update. Here's what it means for the health IT company.
https://www.bizjournals.com/kansascity/news/2018/01/25/cerner-apple-health-records-partnership.html
Cerner Multum™ solution integrates the following databases to provide you with an inclusive drug information resource.
Lexicon Plus - Cerner Multum™ provides a foundational database with comprehensive drug product and disease nomenclature information to link with our clinical information systems and other outside systems.
VantageRx Database - VantageRx™ Database contains drug knowledge in a Microsoft Access format that embeds into your own application and delivers essential clinical content through a series of database tables.
addVantageRx™ SDK – The addVantageRx™ SDK includes all of the database tables in the VantageRx Database, but is delivered as a software development kit (SDK) containing easily implemented components. Organizations receive development interfaces.
SubscribeRx - Cerner Multum provides a hosted solution, called Subscribe Rx, for clients who want to use the software development kit (SDK), but do not want to host the SDK software server components and the clinical databases in their client environments.
https://www.cerner.com/solutions/drug-database
VantageRx: Bringing the pharmacy to your patients:
PRESS RELEASE on Amarantus (AMBS)
Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International
FEBRUARY 06, 2020
New York, NY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary therapeutics and diagnostics, as well as CBD Wellness through its subsidiaries, today announced that its wholly-owned subsidiary MANF Therapeutics has entered into a material transfer agreement (MTA) with Dyadic International, Inc. (Nasdaq:DYAI , or Dyadic) to transfer existing batches of mesencephalic astrocyte-derived neurotrophic factor (MANF) therapeutic protein previously manufactured by third parties in baculovirus and CHO to Dyadic to assist in the evaluation of the potential of Dyadic’s proprietary C1 biologics production platform to manufacture MANF for clinical and commercial use. C1, based on the fungus Myceliophthora thermophila, is a microorganism which enables the development and large scale manufacture of low-cost biologics, and has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologics, including therapeutic proteins such as MANF.
Development rights to MANF were sublicensed from Amarantus to Emerald Organic Products, Inc. in December 2019. MANF has achieved pre-clinical proof of concept in retinitis pigmentosa (RP), retinal artery occlusion (RAO), glaucoma, age-related macular degeneration (AMD), Parkinson’s disease, diabetes, myocardial infarction, as well as several other endoplasmic reticulum stress-related disorders, and has shown the potential to enhance immunological response in pre-clinical studies. Pre-clinical development of MANF is initially being focused on the treatment of orphan ophthalmological diseases and Parkinson’s. MANF has received orphan drug designation from the US FDA for the treatment of RP and RAO.
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Additionally, and more recently, Dyadic is also beginning to explore the use of its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of Adeno-associated viral vectors (AAV), certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.
Please visit Dyadic's website at http://www.dyadic.com for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.
About Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings (AMBS) is a JLABS alumnus biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. The Company is also operating wellness stores in the United States through its majority-owned subsidiary Hempori, Inc.
Hempori
Amarantus owns 51% of Hempori, Inc. The Hempori brand is active in the Hemp industry and has over 75 products that are sold in its own stores in Dallas, Texas and online via Hempori.com. Hempori has developed unique proprietary products in the Hemp industry and is actively engaged with researchers to gather data regarding the utility of its products.
Diagnostics
The Company‘s 80.01%-owned subsidiary Breakthrough Diagnostics, Inc., currently a joint venture with Todos Medical, Ltd. has licensed intellectual property rights to the Alzheimer’s blood diagnostic LymPro Test ® from Leipzig University that was originally developed by Dr. Thomas Arendt, as well as certain rights to multiple sclerosis diagnostic MSPrecise™ and Parkinson’s diagnostic NuroPro. Amarantus entered into a joint venture agreement with Todos Medical, Ltd. (OTCQB: TOMDF) to advance the diagnostic assets, and Todos has exercised its exclusive option to acquire Amarantus’ remaining ownership in Breakthrough in exchange for approximately 49% ownership of Todos. The transaction is expected to close in the first half of 2020. Amarantus also owns approximately 30% of the common shares of Avant Diagnostics, Inc, a tumor analysis company developing Theralink®, the proprietary phosphoprotein tumor analysis platform run using reverse phase protein array (RPPA) platform.
Therapeutics
AMBS’ 50.1%-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer’s aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired Cutanogen Corporation from Lonza Group in 2015 and currently owns 90.1% of that subsidiary. Cutanogen is preparing for pivotal studies with Engineered Skin Substitute (ESS) for the treatment of pediatric life-threatening severe burns. ESS is a regenerative medicine-based, autologous full-thickness skin graft technology originally developed by the Shriner’s Hospital that can be used to treat severe burns, as well as several other catastrophic and cosmetic dermatological indications. AMBS’ wholly-owned subsidiary, MANF Therapeutics Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (“MANF”). MANF Therapeutics is developing MANF-based products as treatments for ophthalmological disorders such as Wolfram Syndrome, Retinitis Pigmentosa and Glaucoma, as well as neurodegenerative diseases such as Parkinson’s disease. MANF was discovered by the Company’s Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS’ proprietary discovery engine PhenoGuard, and believes several other neurotrophic factors remain to be discovered. MANF and ESS have been licensed to Emerald Organic Products, Inc.
For further information please visit www.Amarantus.com, or connect with the Amarantus on Facebook, LinkedIn, Twitter and Google+.
Amarantus Investor and Media Contact:
Gerald Commissiong
President & CEO
Office: 650-862-5391
Email: gerald@amarantus.com
Notice Regarding Forward-Looking Statements
This letter contains forward-looking statements, about the Company’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in the filings with the SEC. Amarantus does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.
1547522887207_5c33aa745c253600048c1b5f_logo.jpg
Source: Amarantus Bioscience Holdings, Inc.
Released February 6, 2020
Nice 860,000 share bid showed up today on ARYC. Sat there all day....no takers
AAPL News: Filmmakers Poised for Big Gains in Hollywood’s ‘Streaming Wars’
https://ih.advfn.com/p.php?pid=nmona&article=81380781
TSLA News: Current Report Filing (8-k) https://ih.advfn.com/stock-market/NASDAQ/tesla-TSLA/stock-news/81627894/current-report-filing-8-k
Nice...I know the company is currently laser focused on rapidly expanding their allergy testing network but you can see a huge opportunity developing when the company expands into other profitable areas.
Interesting link thanks - the future of cancer detection, and every other disease out there will be in simple blood tests..
Below is an exosome test study from last year using Arrayit slide..
https://www.jove.com/video/59177/using-nanoplasmon-enhanced-scattering-low-magnification-microscope
Why would ARYC care about tumor secreted exosomes? If ARYC has microarrays specific to cancer tumor exosomes they could identify specific cancer exosomes within their blood samples. The more/less tumor exosomes within the blood identifies the stage of the cancer tumor. IMO
Cancer tumors have their own specific identifiers. The specific tumor (base) releases its army (troops) within the blood stream called "Tumor secreted exosomes." If this specific exosome is located within blood it identifies the tumor (base.) The tumor secreted exosomes are also circulating looking for a new base station (Tumor) known as (Metastasis.) IMO, but backed up by scientists and publications..
Good article..
https://apple.news/A-STNjHzGQvufDhR7S1Qj3Q
Interesting blood detection cancer test.
Morning SD and silconians.
Not related but is anyone catching the s..t show that is Aurora Cannabis this morning. Quite the show to watch,
Good Morning to everyone @ Silicon Valley Stock Board!
Accenture & Google Cloud Collaborate to Help Life Sciences Companies Advance the Discovery, Development & Delivery of Innovat...
https://ih.advfn.com/stock-market/NASDAQ/alphabet-GOOGL/stock-news/81613653/accenture-google-cloud-collaborate-to-help-life
I never thought of that but in some scenarios it would make a lot of sense.
Repost of a stockholders recent visit to Arrayit Corporation in Silicon Valley (OTC: ARYC)
Posted by: Sloan89RH
Memorandum For Investors/Speculators Concerned About Arrayit Corporation
On Oct 3, 2019, I visited Arrayit Headquarters in Sunnyvale, California. Upon my return home I posted a brief statement about the visit. My comments were, by necessity, general in nature because of the quiet period that Arrayit is honoring as a result of the SEC Form 15. Some on this board appreciated the feedback. Others have accused me of fabricating my account of the visit and not going at all.
As a consequence of the April 1, 2019 disappointment and the subsequent filing of the SEC Form 15 all sorts of rumors, conspiracy theories, speculation, and outright lies were propagated on Social Media. A partial list of these include the following:
. Arrayit is a scam
. Arrayit is bankrupt
. Arrayit operates in a strip mall
. Arrayit is selling off its equipment
. Arrayit is having yard sales to raise money
. Arrayit isn’t paying its rent
. Arrayit has been evicted from its facility
. Arrayit doesn’t produce anything
. Mark isn’t even in the U.S.
. The electricity has been turned off
. Mark is on the run and has left the country
. This pig is being delisted for non-compliance
As a result of the constant stream of BS and innuendo I started to wonder myself if any of the assertions might be true. I certainly didn’t think they were true but I’m sure some reading this also began to wonder. I do much of my own research and I am an accredited investor so the best way for me to confirm or deny the allegations being made was for me to go to California and find out for myself.
Since I will be travelling for the next seven weeks and unable to pay much attention I want to state the following: I went to Arrayit’s headquarters and was fortunate to visit with Rene, Mark, and staff members. I asked lots of questions. Did I get specific definitive answers to all of my questions; the answer is no…because of the constraints imposed as a result of the SEC Form 15. Was I able to get a sense as to whether Arrayit was a profitable going concern and that management was doing their best to execute on its business plan? The answer is a resounding yes. Would I be inclined to add to my holdings at these depressed prices even without the financials? The answer is also yes, and I have for the last few trading days.
In conclusion, my trip was well worth the time and expense. Although I wasn’t able to get all of the answers I was looking for during my visit, I certainly was able to debunk the nonsense outlined in my second paragraph. I am very comfortable with my investment and willing to be patient with Arrayit’s management strategy.
Just released AMBS Letter to Shareholders: Interesting business plan outlined.
PRESS RELEASES
Amarantus Releases Letter to Shareholders
FEBRUARY 04, 2020
New York, NY, Feb. 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary therapeutics and diagnostics, as well as CBD Wellness through its subsidiaries, today released a letter to shareholders:
Dear Shareholders,
On Thursday, January 30th, 2020, Amarantus announced the acquisition of a controlling interest in CBD Wellness Company Hempori, Inc, based in Dallas, TX. This transaction was completed 9 months after announcing that we were formally evaluating expanding into the legal hemp industry. With the acquisition of Hempori, Amarantus has added a cash-flow generating business unit that has the potential to drive equity value substantially while the investments we have made into our biopharmaceutical and diagnostics portfolios continue to mature. Given Amarantus’ existing partnerships with Emerald Organic Products in therapeutics, and with Todos Medical and Avant Diagnostics in the diagnostics lab testing space, we now have the upside potential of science-driven biotechnology development funded by other entities, combined with a growing cash-generating business on the high-value end of the emerging CBD industry. We believe this combination of underlying businesses presents shareholders with an exceptional opportunity as the Company is on the cusp of leading biopharmaceutical solutions that have the potential to save lives and dramatically improve patient outcomes being funded by other entities, while Amarantus works with our Hempori customers to determine exactly how CBD can potentially improve symptoms associated with ailments that are poorly managed with traditional healthcare solutions. We believe the CBD movement emerging in the US is driven largely by dissatisfaction with the pharmaceutical industry that relies heavily on prescription drugs to treat symptoms caused by other prescription drugs to drive growth, and we believe there may be wellness alternatives that could ultimately lead to improved outcomes at lower overall healthcare costs, with CBD being a driving force moving the market in this direction.
Hempori Acquisition
After over 18 months of due diligence into the CBD space in general, and over 12 months of due diligence into Hempori specifically, we decided to invest in the CBD retail space for the following reasons:
CBD Space in General
Cowen Research expects the US CBD Market to grow from ~$1 billion in 2018 to ~$16 billion by 2025;
In early 2019, Cowen research conducted a market survey that showed 7% of respondents had used CBD as a supplement, and we expect the percentage of people using CBD will go up annually as the clinical utility of CBD (and other non-psychoactive cannabinoids) products becomes clearer through collection and analysis of user data;
Significant education is required to educate consumers about CBD, leading to a high-value being placed on ‘touching the customer,’ and on being able to engage in data collection on customer behavior and experience, with high gross margins for retailers;
We believe most consumers and prospective buyers of CBD products are generally people with medical problems looking to identify alternative wellness solutions for symptoms that are poorly managed by traditional healthcare products. These customers are looking to physically engage with the providers of CBD-based solutions to be educated on how best to use CBD products, and are willing to provide meaningful feedback to help improve the overall customer experience for their communities of disease sufferers;
Plant-based solutions became a key investing trend in 2019, with several successful IPOs (eg Beyond Meat), and the introduction of products into the mainstream marketplace that underscore an increasing this increasing demand fin the marketplace.
Hempori
Hempori’s market research identified that the vast majority of its customers are driven by a desire for symptom improvement related to an underlying medical condition, with strong customer retention having been demonstrated over the last 12 months. We have also heard from customers that Hempori’s products may be significantly better than those of competitors in the marketplace. We reviewed several anecdotal case studies suggesting that there may be benefit to using Hempori products, although further research and objective data generation will ultimately be required to be able to make claims. These same customers seeking specific individual solutions also tend to identify other products that they believe may improve their health and wellness, and therefore commit additional monthly resources to purchasing CBD products;
Hempori stores offer an attractive go-to-market strategy in CBD that leaves flexibility to adapt to emerging trends and products, while continually capturing real-world consumer data to make product and marketing decisions to improve the customer experience. This will allow us to tailor products and education services for specific categories of customers;
Hempori has begun to leverage its storefront properties to drive online sales to its loyal customer base through monthly automatic re-orders, while beginning to build strong brand awareness as customers share their experiences, leading to genuine online engagement about how Hempori’s products could potentially help new customers;
The team at Hempori recognizes that CBD is part of a larger ‘plant-based’ wellness trend in the overall marketplace where people believe that wellness solutions derived from plants grown naturally may improve human and animal health in natural ways that are fundamentally different from solutions derived from chemical synthesis-based compounds (including an emerging view, for example, that broad spectrum distillate CBD has greater potential vs. CBD isolate). We are working with Hempori to evaluate adding other plant-based solutions (mushrooms, or others) to the storefront offering in order to deliver our customers with more options to attempt to improve their health and well-being.
We intend to spend the first quarter looking to identify new sales channels for Hempori’s leading products, and invite shareholders in Dallas to visit the Hempori stores in-person, and for those not in the Dallas area interested in trying Hempori products to order products online. We would like to get feedback on your experience so that we can continue to improve the Hempori experience. Hempori’s leading products are:
Hot Pain Cream Lotion: https://hempori.square.site/product/1000mg-hot-pain-cream-lotion-hempori-cbd/26?cs=true
Himalayan Bath Salts: https://hempori.square.site/product/bella-vita-himalayan-bath-salts-500mg/42?cs=true
Tinctures: https://hempori.square.site/product/5000mg-tincture-hempori-cbd/14
Hempori has several other products available at online store, including dog treats. Hempori’s online store is at: https://hempori.square.site/.
Todos Medical option to acquire Provista Dx and Management Changes
On January 9th, 2020, our blood testing joint venture partner Todos Medical announced that it entered into an exclusive option agreement to acquire breast cancer blood testing company Provista Diagnostics. Concurrent with this announcement, I was appointed as CEO of Todos primarily to help Todos implement its plans to bring its blood testing technologies into the US market and list its common stock onto a US national stock exchange, which would ultimately create substantial value for Amarantus as a significant shareholder in Todos. As part of this initiative, we are working to complete the all-stock acquisition of Amarantus’ subsidiary Breakthrough Diagnostics into Todos Medical in the near future. Breakthrough is developing the Alzheimer’s blood diagnostic LymPro Test, that is based upon the scientific theory that Alzheimer’s is essentially cancer of non-dividing cells that get stuck in an immune-mediated post-mitotic aberrant cell cycle cellular division process that causes the overproduction of canonical Alzheimer’s proteins amyloid-beta and tau, as well as several other markers of Alzheimer’s. Prior peer-reviewed work suggests LymPro has significant clinical value, and a recent interim analysis of 20 subjects in an ongoing clinical study being conducted at Leipzig University seeking to evaluate the relationship between amyloid PET radiolabeled tracers and LymPro demonstrated strong concordance between amyloid PET and LymPro scores (p=0.000002 and r = 0.85). The second half of that study completed enrollment in the fourth quarter of 2019, and we expect data to be available in the near future that will drive significant value in the race to develop a simple blood test for Alzheimer’s disease. Breakthrough is at the forefront of this effort based upon the work of Dr. Thomas Arendt, a pioneer in the field who has been studying these concepts for over 20 years.
With regards to the near-term commercial focus of Todos which is in the area of breast cancer, Provista Diagnostics has received investments of over $50M which it has used to develop a stable, antibody-based simple blood test that measures the presence of Tumor-associated Auto-Antibodies (TAAbs) and Serum Protein Biomarkers (SRPs) that shows strong negative predictive value (97-99%) for the presence of breast cancer in BI-RADS III/IV population (high percentage of ‘dense breast’ subjects), as well as in the 25-50 year-old population for which fewer screening alternatives exist because of CDC’s recent guideline changes moving the age for initial mandatory mammogram screening for breast cancer to 50 years old because of the risk associated with cumulative exposure to radioactive agents that potentially cause more cancers than they find. With analytical and clinical validity now well-established in the peer-reviewed literature for its Videssa® breast cancer blood test after testing in prospective clinical studies in over 1100 human subjects, and a CLIA/CAP certified lab in place to support product launch, Provista will now be focused on reimbursement-enabling clinical studies that we expect will allow Videssa to demonstrate its value to payers by mitigating the need for unnecessary biopsies. Based on projections derived from certain clinical sites in Videssa’s most recent clinical trials, unnecessary biopsies may be reduced by up to over 43% with the data provided by Videssa in the BI-RADS IV population, with even greater value in the BI-RADS III population, where unnecessary biopsies were expected to be reduced by 87%. On a combined BI-RADS III/IV basis, reduction in biopsy was projected to be over 45%.
The BI-RADS III/IV (dense breast) population represents anywhere between 20-60% of the population, depending on the country of origin, and is the same patient population that Todos’ total biochemistry infrared analysis (TBIA)TM-B2 assay is seeking to provide information for. Given feedback from FDA on the number of patients required for TM-B2’s ultimate approval (close to 2,000 patients), we believe Videssa represents the perfect ‘piggyback’ opportunity for TM-B2 to further train its algorithm and rapidly get the breadth of analytical and clinical data required to establish analytical and clinical utility to an FDA standard. Upon closing of the Provista acquisition, we believe Videssa’s strong data will allow it to sequentially move from its existing CPT code stacking strategy for reimbursement towards a unique code that will allow Videssa to gain value-based, stable reimbursement from third-party payers and dramatically increase the pool of physicians and patients who routinely use Videssa to help make decisions about whether to seek additional more invasive testing for breast cancer. In parallel, Todos’ TM-B1 and TM-B2 assays will gain valuable information by piggybacking on Videssa’s patient flow to will improve their accuracy by training TBIA’s AI-driven algorithm in prospective studies to not only demonstrate equivalence to Videssa’s negative predictive value data, but also show superior data in positive predictive value that could ultimately allow TM-B1 assay to become a credible alternative to mammograms.
According to a recent research report by Absolute Reports, the global Breast Biopsy market size will grow from under $550 Million in 2017 to over $1 billion by 2023, with an estimated CAGR of 11.0%. Major factors fueling market growth are the rising incidences of breast cancer among women and increase in breast cancer screening programs in different countries. In addition to this, the increase in reimbursement rates in U.S. for image-guided biopsy and the growing demand for less-invasive breast biopsy are propelling the growth of the market. The breast cancer treatment market is expected to grow from $16 billion annually in 2018 to over $35 billion by 2025. It has been demonstrated that early diagnosis for breast cancer leads to substantially improved patient outcomes and lower costs. The size of the overall mammogram breast screening market is expected to surpass $5.4 billion annually in the United States by 2022, making it an increasingly costly burden to the US healthcare system. The breast cancer blood testing market is over $2 billion annually, with significant innovation needed in light of the recent questions regarding in the value of genetic testing in the breast cancer space. We believe Videssa could provide significant additional information to determine if a patient should be advanced to more invasive screening to rule-in breast cancer, prior to invasive preventive treatment options. In light of these recent developments, we believe the Todos-Provista merger will provide tremendous value for the healthcare system and lead to overall improved patient outcomes.
Emerald Organic Sublicense and Recapitalization Update
The Company’s plan to complete its recapitalization has taken significant strides forward in the recent weeks with the progress at Todos and acquisition of Hempori. The Company’s previously announced transaction with Emerald on its therapeutics portfolios is beginning to make progress, and we expect to make announcements on some of that progress in the near future. Amarantus is continuing to negotiate with its Elto Pharma JV partner Psychogenics, Inc. and Emerald for the rights to eltoprazine to be added to the Company’s existing license with Emerald for MANF and ESS.
Taken together, in the last several month the Company has added significant equity value to its balance sheet via the Emerald transaction, with additional equity to be added via the completion of the sale of Breakthrough Diagnostics to Todos Medical. These transactions are expected to more than offset our outstanding liabilities (the majority of which will be equitized as we achieve certain value-building recapitalization milestones), and pave the way for value appreciation to occur through growth in our recently-acquired Hempori business unit, as well as delivery on various milestones in our partnered Cutanogen, MANF Therapeutics, Elto Pharma, Avant Diagnostics, and Breakthrough Diagnostics business units.
We believe the Company has positioned itself in preparation for its pending Regulation A offering to be able to raise capital based on existing net value (combination of the value of Emerald equity ownership plus the royalty on therapeutic portfolio, the value of equity ownership in Todos and the value of equity ownership in Avant), and a growing business in Hempori with an attractive profile that, through proper execution, has a highly profitable future cash-flow model to justify substantial enterprise value for the Company’s equity holders. With the majority of the recapitalization structures now in place, we have a better concept of the right management to take the Company forward into the future as I focus on executing in the different business units the Company owns. With this structure now in place, we intend to complete management changes Amarantus announced it was evaluating in Q1/2019 as funding becomes available through the Reg A to retain the right executive to take the Company into the future.
We would like to thank you for continuing to be a shareholder and will provide updates as the Company continues to make progress in its plans.
Warm Regards,
Gerald Commissiong
President & CEO
About Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings (AMBS) is a JLABS alumnus biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. The Company is also operating wellness stores in the United States through its majority-owned subsidiary Hempori, Inc.
Hempori
Amarantus owns 51% of Hempori, Inc. The Hempori brand is active in the Hemp industry and has over 75 products that are sold in its own stores in Dallas, Texas and online via Hempori.com. Hempori has developed unique proprietary products in the Hemp industry and is actively engaged with researchers to gather data regarding the utility of its products.
Diagnostics
The Company‘s 80.01%-owned subsidiary Breakthrough Diagnostics, Inc., currently a joint venture with Todos Medical, Ltd. has licensed intellectual property rights to the Alzheimer’s blood diagnostic LymPro Test ® from Leipzig University that was originally developed by Dr. Thomas Arendt, as well as certain rights to multiple sclerosis diagnostic MSPrecise™ and Parkinson’s diagnostic NuroPro. Amarantus entered into a joint venture agreement with Todos Medical, Ltd. (OTCQB: TOMDF) to advance the diagnostic assets, and Todos has exercised its exclusive option to acquire Amarantus’ remaining ownership in Breakthrough in exchange for approximately 49% ownership of Todos. The transaction is expected to close in the frist half of 2020. Amarantus also owns approximately 30% of the common shares of Avant Diagnostics, Inc, a tumor analysis company developing Theralink®, the proprietary phosphoprotein tumor analysis platform run using reverse phase protein array (RPPA) platform.
Therapeutics
AMBS’ 50.1%-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer’s aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired Cutanogen Corporation from Lonza Group in 2015 and currently owns 90.1% of that subsidiary. Cutanogen is preparing for pivotal studies with Engineered Skin Substitute (ESS) for the treatment of pediatric life-threatening severe burns. ESS is a regenerative medicine-based, autologous full-thickness skin graft technology originally developed by the Shriner’s Hospital that can be used to treat severe burns, as well as several other catastrophic and cosmetic dermatological indications. AMBS’ wholly-owned subsidiary, MANF Therapeutics Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (“MANF”). MANF Therapeutics is developing MANF-based products as treatments for ophthalmological disorders such as Wolfram Syndrome, Retinitis Pigmentosa and Glaucoma, as well as neurodegenerative diseases such as Parkinson’s disease. MANF was discovered by the Company’s Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS’ proprietary discovery engine PhenoGuard, and believes several other neurotrophic factors remain to be discovered. MANF and ESS have been licensed to Emerald Organic Products, Inc.
For further information please visit www.Amarantus.com, or connect with the Amarantus on Facebook, LinkedIn,Twitterand Google+.
Amarantus Investor and Media Contact:
Gerald Commissiong
President & CEO
Office: 650-862-5391
Email: gerald@amarantus.com
Notice Regarding Forward-Looking Statements
This letter contains forward-looking statements, about the Company’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in the filings with the SEC. Amarantus does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.
1547522887207_5c33aa745c253600048c1b5f_logo.jpg
Source: Amarantus Bioscience Holdings, Inc.
Released February 4, 2020
Looks like this company is going places and definitely doing a bullish pattern right now. Looks good.
Yep, AMBS looking good today.
You may be right but I think Avant's relationship with Infusion 51a would prevent that from happening.
I believe Arrayit will be able to purchase Avant if they choose to do so.
Well that would be great if it all works out.
Followers
|
11
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
159
|
Created
|
02/04/20
|
Type
|
Free
|
Moderator techmover | |||
Assistants stock detective BBstocks77 PennyStock Alert DDStocks SK510 Sloan89RH |
Posts Today
|
0
|
Posts (Total)
|
159
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |